WO1996004915A9 - Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes - Google Patents
Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenesInfo
- Publication number
- WO1996004915A9 WO1996004915A9 PCT/US1995/010110 US9510110W WO9604915A9 WO 1996004915 A9 WO1996004915 A9 WO 1996004915A9 US 9510110 W US9510110 W US 9510110W WO 9604915 A9 WO9604915 A9 WO 9604915A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydrogen
- lower alkyl
- carbon atoms
- compound
- Prior art date
Links
- 206010001897 Alzheimer's disease Diseases 0.000 title claims abstract description 46
- 150000002990 phenothiazines Chemical class 0.000 title claims description 10
- 150000005075 thioxanthenes Chemical class 0.000 title claims description 8
- 238000009825 accumulation Methods 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 57
- -1 hydrogen- Chemical class 0.000 claims description 53
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000011780 sodium chloride Substances 0.000 claims description 24
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 23
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 229960001076 Chlorpromazine Drugs 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 150000002431 hydrogen Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000001931 aliphatic group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- ZEWQUBUPAILYHI-UHFFFAOYSA-N Trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 9
- 229960002324 Trifluoperazine Drugs 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Tranquisan Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000004940 Nucleus Anatomy 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000004429 atoms Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-UHFFFAOYSA-N hydrogen atom Chemical group [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000001302 tertiary amino group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 abstract description 4
- 229950000688 Phenothiazine Drugs 0.000 abstract description 4
- PQJUJGAVDBINPI-UHFFFAOYSA-N Thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 abstract description 4
- 210000004027 cells Anatomy 0.000 description 101
- 235000018102 proteins Nutrition 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 46
- 108090001123 antibodies Proteins 0.000 description 32
- 102000004965 antibodies Human genes 0.000 description 32
- 101700021037 PHF1 Proteins 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 210000004556 Brain Anatomy 0.000 description 24
- 206010029260 Neuroblastoma Diseases 0.000 description 24
- 229920001307 poly(hydroxymethylethylene hydroxymethyl formal) Polymers 0.000 description 24
- 239000002609 media Substances 0.000 description 17
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 16
- 108010041174 tau-1 monoclonal antibody Proteins 0.000 description 15
- 210000001519 tissues Anatomy 0.000 description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000005755 formation reaction Methods 0.000 description 12
- 230000000865 phosphorylative Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drugs Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000003656 tris buffered saline Substances 0.000 description 11
- 210000004408 Hybridomas Anatomy 0.000 description 10
- QNDVLZJODHBUFM-WFXQOWMNSA-N Okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 9
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 9
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000013498 tau Proteins Human genes 0.000 description 8
- 108010026424 tau Proteins Proteins 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 108010045030 monoclonal antibodies Proteins 0.000 description 7
- 102000005614 monoclonal antibodies Human genes 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 230000004075 alteration Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002569 neurons Anatomy 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 235000021251 pulses Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 229960000060 monoclonal antibodies Drugs 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 230000003000 nontoxic Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940022766 EGTA Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 210000002682 Neurofibrillary Tangles Anatomy 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 230000003467 diminishing Effects 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000000698 schizophrenic Effects 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 239000007759 RPMI Media 1640 Substances 0.000 description 3
- 210000002356 Skeleton Anatomy 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001605 fetal Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000000007 protein synthesis inhibitor Substances 0.000 description 3
- 230000000717 retained Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- WNTYBHLDCKXEOT-UHFFFAOYSA-N Acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N Chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 2
- 229960001552 Chlorprothixene Drugs 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010012271 Dementia Alzheimer's type Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100008623 FYB1 Human genes 0.000 description 2
- 101700018360 FYB1 Proteins 0.000 description 2
- 229960002690 Fluphenazine Drugs 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine dihydrochloride Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 210000001320 Hippocampus Anatomy 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N Levomepromazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N Mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 229960000300 Mesoridazine Drugs 0.000 description 2
- 229940042053 Methotrimeprazine Drugs 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XSCGXQMFQXDFCW-UHFFFAOYSA-N Triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 2
- 229960003904 Triflupromazine Drugs 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960000276 acetophenazine Drugs 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229960004615 levomepromazine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 230000005015 neuronal process Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 229960003598 promazine Drugs 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000026731 protein phosphorylation Effects 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960004660 thiothixene Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZYZCGGRZINLQBL-JCGNTXOTSA-N (5R,8R,11R,12S,15S,18S,19S,22R)-15-[3-(diaminomethylideneamino)propyl]-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylidene-8-(2-methylpropyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopenta Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 ZYZCGGRZINLQBL-JCGNTXOTSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- RBBDPYXZGDGBSL-UHFFFAOYSA-N 2,3-dimethylnaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(O)=O)=C(C)C(C)=CC2=C1 RBBDPYXZGDGBSL-UHFFFAOYSA-N 0.000 description 1
- DPXWHZUTDZONDB-UHFFFAOYSA-N 2-[2-(4-methoxyphenyl)-2-oxoethyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=CC=C1C(O)=O DPXWHZUTDZONDB-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VRQVVMDWGGWHTJ-UHFFFAOYSA-N 3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine Chemical compound C1=CC=C2N(CC(C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-Chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7H-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 210000003050 Axons Anatomy 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000036881 Clu Effects 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 210000001787 Dendrites Anatomy 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 210000001353 Entorhinal Cortex Anatomy 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical group CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101700014166 LRCH1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 241000528415 Moana Species 0.000 description 1
- GFBKORZTTCHDGY-UHFFFAOYSA-N N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2C1=CCCN1CCN(C)CC1 GFBKORZTTCHDGY-UHFFFAOYSA-N 0.000 description 1
- 206010061311 Nervous system neoplasm Diseases 0.000 description 1
- 210000002241 Neurites Anatomy 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- IXBQSRWSVIBXNC-HSKGSTCASA-N Nodularin Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C\C)/C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 IXBQSRWSVIBXNC-HSKGSTCASA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229960000762 Perphenazine Drugs 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M Potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 102000006831 Protein phosphatase 2C family Human genes 0.000 description 1
- 108010047313 Protein phosphatase 2C family Proteins 0.000 description 1
- 101710005031 RMDN1 Proteins 0.000 description 1
- 101710030983 RNF138 Proteins 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710029702 TICAM1 Proteins 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 101710021425 TRIM69 Proteins 0.000 description 1
- 102100003447 TRIM69 Human genes 0.000 description 1
- 210000003478 Temporal Lobe Anatomy 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2R,3R,5R,7R,8S,9S)-2-[(1S,3S,4S,5R,6R,7E,9E,11E,13Z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[(2S)-4-[[(2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- GFEYTWVSRDLPLE-UHFFFAOYSA-L dihydrogenvanadate Chemical compound O[V](O)([O-])=O GFEYTWVSRDLPLE-UHFFFAOYSA-L 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N dl-Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010065793 nodularin Proteins 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960003357 pamabrom Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- SVIHRJIEKRFYDN-UHFFFAOYSA-N propanamide Chemical group [CH2]CC(N)=O SVIHRJIEKRFYDN-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108010005709 protein kinase C kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Definitions
- This invention relates to methods for preventing or treating Alzheimer's Disease. More specifically, the methods comprise administering to a patient an amount of a phenothiazine or a thioxanthene effective to prevent or diminish the accumulation of abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease.
- Alzheimer's Disease is a progressive neurodegenerative disorder affecting 7% of the population over 65 years of age and characterized clinically by progressive loss of intellectual function.
- Alzheimer's Disease is characterized by the accumulation of abnormally phosphorylated, paired helical filaments (PHFs) , which accumulate as neurofibrillary tangles in neuronal cell bodies and in the neurites of the neuritic plagues.
- PHFs also are present in neuronal processes, such as axons and dendrites. As much as 90% of the PHF in the cortex of the average Alzheimer case is present in the neuronal processes rather than in the plague or tangle ( olozin, B.L. and Davies, P. Ann. Neurol. 22;521-526 (1987)).
- MAPs neurofilaments and other icrotubule associated proteins
- Monoclonal antibodies have been generated by the inventors of the present invention which are reactive with PHFs in the brain tissue of Alzheimer's Disease patients, and in most cases, minimally or not cross reactive with proteins in the normal adult brain. These antibodies react with abnormally phosphorylated epitopes on PHF proteins in the Alzheimer's brain which are modified as a result of the disease process.
- the ability to inhibit the production of abnormally phosphorylated PHF proteins including tau, other MAPs and neurofilament proteins by blocking epitopes recognized by these antibodies is expected to interfere or prevent the formation and acccumulation of PHF, and therefore inhibit or prevent the progression of Alzheimer's disease. To date, however, it has not been possible to consistently induce the formation of abnormally phosphorylated PHFs epitopes in abundance either in vivo or in vitro.
- Shea, T.B., et al. reported that aluminum salts induce the accumulation of neurofilaments in neuroblastoma cells (Shea, T.B., et al. Brain Res. 492:53-64 (1989)).
- the neurofilaments produced by Shea, et al. have not been shown to correlate with PHFs associated with Alzheimer's Disease.
- Ko, Li-wen, et al. reported the alleged expression of epitopes associated with neurons in Alzheimer's Disease in the human neuroblastoma cell line IMR32 grown in a differentiation medium using polyclonal antibodies to PHF epitopes (Ko, Li-wen, et al. A . J. Path. 136(4) :867-879 (1990)) .
- the present invention which is directed to a tissue culture model in which Alzheimer's Disease epitopes are continually and abundantly expressed, fulfills a great need in this field.
- the present invention provides an in vitro model cell system which expresses abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease, which comprises neuroblastoma cells which have been treated with an amount of a protein phosphatase inhibitor effective to render homogenate from the cells treated therewith immunoreactive with antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes.
- the model system of this invention may be used for determining whether an agent is capable of preventing or diminishing the accumulation of abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease.
- the present invention also provides a method for treating or preventing Alzheimer's Disease which comprises the administration of a drug which blocks the accumulation of abnormally phosphorylated, paired helical epitopes associated with Alzheimer's Disease.
- Figure 1 represents the time course for OkA treatment.
- Confluent layers of MSN cells were incubated at 37°C for 0 minutes and 4 hours with the KRP containing 0.05% DMSO (Controls) , or 30 minutes, 90 minutes, 4 hours, 10 hours, and 24 hours with 1 ⁇ M OkA.
- the cells were harvested and boiled to generate heat-stable fractions. Twenty ⁇ g of protein per lane was resolved by SDS-PAGE, and gels were electrophoretically transferred to nitrocellulose. Blots were immunostained with the Alz-50, Tau-1, 188, PHF-1, NP-8, and T3-P antibodies. The arrow beside the PHF-1 blot points to the 68-kDa protein, which is only apparent after OkA treatment.
- Figure 2 represents the dose-response curve for OkA treatment.
- MSN cells were incubated with 5 nM, 50 nM, 1 ⁇ M, and 50 ⁇ M OkA in KRP for 4 hours at 37°C. Heat-stable fractions were prepared and used for western blot analysis as in Figure 1. Note that the 50 ⁇ M OkA-treated sample in the Alz-50 blot represents only 13 ⁇ g of protein.
- Figure 3 represents the effects of protein synthesis inhibition. MSN cells were incubated at 37°C for 90 minutes with 1 ⁇ M OkA in the absence or presence of 100 ⁇ M anisomycin. Heat-stable fractions were prepared, and 30 ⁇ g of protein was analyzed by western blotting as in Figure 1.
- Figure 4 represents the treatment of MSN cell lysates with OkA: Effects of alkaline phosphatase.
- MSN cells were collected by centrifugation and resuspended in KRP containing 4 mM PMSF, 25 ⁇ M leupeptin, and 2 mM EGTA. The cell suspension was sonicated for 2 seconds, and the resulting lysate was incubated at 37°C for 60 minutes in the absence or presence of 10 ⁇ M OkA. Additional samples were treated with 50 nM OkA. Thirty ⁇ g of the respective heat-stable fractions were loaded per lane.
- Duplicate blots were incubated at 37°C for 24 hours with 20 units of alkaline phosphatase per ml of pH 8.0 buffer in the presence of 10 mM PMSF (+) . The blots were then immunized with the Alz-50, Tau-1, 188, PHF-1, T3P, and NP-8 antibodies.
- Figure 5A represents the 32 P-labeling of tau using pulse-chase.
- MSN cells were preincubated at 37°C for one hour with 2.5 mCi of 3 P-orthophosphoric acid in phosphate-free medium. The cells were then chased for 90 minutes with KRP in the absence (control) or presence of l ⁇ M OkA. Heat-stable supernatants were further enriched for tau by perchloric acid
- Figure 5B represents the 32 P-labeling of tau using pulse.
- Cells were preincubated for 30 minutes with labeled orthophosphoric acid at the end of which time, 1 ⁇ M OkA acid was introduced into one sample.
- heat-stable supernatants were isolated and subjected to PCA and methanol precipitation. Blots were stained with Alz-50 and subsequently subjected to autoradiography.
- Figure 6 represents the 35 S-methionine labelling of tau.
- MSN cells were pulse labeled overnight in methionine- free medium containing 200 ⁇ Ci per ml isotopic methionine. The cells were subsequently chased for 90 minutes with KRP containing 2 mM unlabelled methionine with the indicated additions. Heat-stable supernatants were treated with PCA, and the PCA soluble protein methanol-precipitated for gel- loading. Blots were stained with Alz-50, and subjected to autoradiography.
- Figure 7 represents the immunoreactivity of antibodies Alz-50, PHF-1, TG3, TG4, MC2, MC6, and MC15 with normal and Alzheimer's Disease brain, and with MSN cells before (MSN-) and after treatment (MSN+) with okadaic acid.
- the data from brain tissue are the mean values derived from studies of mid-temporal cortex from five normal cases and five cases of Alzheimer's Disease.
- Values from MSN cells are from a single experimental series in which 1 micromolar okadaic acid was added to triplicate MSN cell cultures for 90 minutes prior to harvest of the cells. Each sample (tissue or cell homogenate) was assayed at 8 dilutions, in duplicate.
- the units on the Y axis are arbitrary units of immunoreactivity.
- Figure 8 represents the immunoblot of neuroblastoma (MSN-A) cells expressing paired helical filament epitopes as a control, and after treatment with trifluoperazine and chlorpromazine.
- Figure 9A represents relative ADAP concentrations in Broad an area 10 in Alzheimer's Disease patients (AD) , normal controls (NC) , and schizophrenic patients on chlorpromazine (RX) .
- Figure 9B represents relative ADAP concentrations in Broadman area 38 in Alzh_imer's Disease patients (AD), normal controls (NC) , and schizophrenic patients on chlorpromazine (RX) .
- the present invention provides an in vitro model cell system which expresses abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease, said system comprising neuroblastoma cells which have been treated with an amount of a protein phosphatase inhibitor effective to render homogenate from the cells treated therewith immunoreactive with antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes.
- the model system of the present invention is produced by treating neuroblastoma cells with an amount of a protein phosphatase inhibitor effective to render homogenate from the cells treated therewith immunoreactive with antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes.
- the neuroblastoma cells useful in the present invention are neuroblastoma cells isolated from the nervous system tumors of children which contain tau, neurofilament proteins, and other neuronal proteins. These cells express express little, if any, abnormally phosphorylated, paired helical filament epitopes until treated with the phosphatase inhibitor.
- the neuroblastoma cells are human cells deposited with the American Type Culture Collection under ATTC Accession No. CRL 11253.
- the protein phosphatase inhibitor is any inhibitor which induces the expression of abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease in neuroblastoma cells treated therewith.
- the protein phosphatase inhibitor is okadaic acid, calyculin A, microcystin-LR, nodularin and phenylarsine oxide.
- the protein phosphatase inhibitor is okadaic acid.
- the amount of protein phosphastase inhibitor used to treat the neuroblastoma cells is an amount effective to induce expression of abnormally phosphorylated, paired helical filament epitopes in the cells treated with that inhibitor.
- the concentration of the inhibitor is between 0.1 and 10 ⁇ M. Most preferably, the concentration is 1.0 ⁇ M. However, the particular optimal concentration will depend upon the inhibitor and cells used.
- the expression of abnormally phosyphorylated, paired helical filament epitopes may be detected using antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes. The epitopes are detected by Western blot analyses or by quantitative ELISA as described in the Experimental Details Section.
- the antibodies may be polyclonal or monoclonal, and are preferably monoclonal.
- the antibodies may be prepared from PHFs isolated from Alzheimer's patients using known procedures.
- the PHFs are isolate 1 and purified using immunoaffinity as descrir ⁇ d in Vincent, I.J. and Davies, P. Proc. Natl. Acad. Sci. i 89:2878-2882 (1992) .
- immunoaffinity As descrir ⁇ d in Vincent, I.J. and Davies, P. Proc. Natl. Acad. Sci. i 89:2878-2882 (1992) .
- twenty grams of cor* al tissue from postmortem Alzheimer's patients is homogeni d in 10 vol. of Tris-buffered saline (TBS; 0.1 M Tris base/0.14 M NaCl, pH 7.4) using a Polytron operating at a setting of 5 for two 30 second bursts.
- the homogeneate is centrifuged at 27,000 x g for 30 minutes at 4°C, and the supernatant is applied to the immunoaffinity column.
- a monoclonal antibody useful for affinity purifica ion is Ab42 (IgG) , a class of switch clone of Alz-50 producec ⁇ cording to published protocol (Spira, G., et al. J. Immunol. Methods 74:307-313 (1984).
- Ab42 IgG
- Approximately 20 mg of protein A-purified Ab42 is dialyzed into 0.1 M sodium phosphate buffer (pH 8.1) and mixed with 10 ml of washed Affi- Gel 10 (Bio-Rad) . The mixture is incubated on a rotary shaker for 30 minutes at room temperature.
- a volume of 0.1 ethanolamine (pH 8.1) equal to that of the gel/antibody mixture is added and the incubation is continued for 1 hour.
- the coupling efficiency is generally >90%.
- the immunoadsorbent is poured into a column and washed with TBS. The column is maintained at 4°C and all chromatography steps are conducted at this temperature. Before application of sample, the column is treated with at least 2 bed vol. of eluting buffer (3 M potassium thiocyanate) followed by 5 bed vol. of TBS. The 27,000 x g supernatant is loaded onto the immunoaffinity column at a flow rate of approximately 25 ml/hr. Nonspecific binding is reduced by washing the immunoadsorbent with at least 30 bed vol.
- mice are immunized with the antigen purified as above by intraperitoneal injection of 10 to 20 micrograms of protein per mouse per injection. Mice are immunized 4 or 5 times before removal of spleens for the production of hybridoma cells by standard protocols. Hybridomas are tested for the production of specific antibodies which react to Alzheimer's brain tissue by ELISA and immunocytochemistry.
- the antibodies have high reactivity with Alzheimer's brain tissue and little or no reactivity with brain tissue from normal individuals.
- the antibodies are selected from the group consisting of Alz-50, PHF-1, TG3, TG4, MC2, MC6, and MC15.
- hybridomas secreting these antibodies have been deposited with the American Type Culture Collection, Rockville, Maryland: Alz-50 is secreted from the hybridoma deposited under ATCC Accession Number HB9205; PHF-1 is secreted from the hybridoma deposited under ATCC Accession Number 11743; TG3 is secreted from the hybridoma deposited under ATCC Accession Number 11744; TG4 is secreted from the hybridoma deposited under ATCC Accession Number 11745; MC2 is secreted from the hybridoma deposited under ATCC Accession Number 11737; MC6 is secreted from the hybridoma deposited under ATCC Accession Number 11740; and MC15 is secreted from the hybridoma deposited under ATCC Accession Number 11741.
- the model system of the present invention and the antibodies above may be used for determining whether an agent or drug is capable of prever ng or decreasing Alzheimer's Disease activity, namely th accumulation of abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease. Accordingly, the present invention also provides a method for determining whether an agent is capable of preventing or diminishing the accumulation of abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease.
- That method comprises (a) treating neuroblastoma cells with an amount of a protein phosphatase inhibitor effective to permit expression of abnormally phosphorylated, paired helical filament epitopes in the treated cells, thereby rendering homogeneate from the cells immunoreactive with antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes; (b) either concomitantly or thereafter adding to the treated cells an agent suspected of being capable of preventing or diminishing the accumulation of abnormally phosphorylated, paired helical filament epitopes; (c) adding to the treated cells antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease; (d ⁇ analyzing homogenate from the cells for immunoreactivity with the antibodies; and (e) determining whether the agent has caused the level of immmunoreactivity between homogenate from the neuroblastoma cells and the antibodies to decrease, said decrease being indicative that the agent has prevented or diminished the accumulation of abnormally phosphoryl
- the present invention also provides a screening kit for use in determining whether an agent is capable of preventing or diminishing the accumulation of abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease, said kit comprising (a) neuroblastoma cells; (b) a protein pho ⁇ nhatase inhibitor which is capable of causing the neuroblastoma cells to express abnormally phosphorylated, paired helical filament epitopes when the cells are treated therewith, thereby rendering homogenate from the treated cells immunoreactive with antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes; and (c) antibodies which specifically bind to abnormally phosphorylated, paired helical filament epitopes expressed by the neuroblastoma cells treated with the protein phosphatase inhibitor.
- phenothiazine compounds i.e. trifluoperazine and chlorpromazine (CPZ)
- CPZ chlorpromazine
- chlorpromazine is effective in decreasing Alzheimer's activity
- the phenothiazines and structurally similar compounds such as thioxanthenes described below display the same profile of activity in the model system and assays described herein as chlorpromazine
- the phenothiazines and thioxanthenes are also effective in preventing or decreasing Alzheimer's activity, and therefore are effective in treating or preventing Alzheimer's Disease.
- the present invention also provides a method for treating or preventing Alzheimer's Disease in a subject in need of such treatment or prevention which comprises administering an amount of a phenothiazine or a thioxanthene effective to prevent or diminish the accumulation of abnormally phosphorylated, paired helical filament epitopes associated with Alzheimer's Disease.
- the phenothiazines useful in the invention have the structural skeleton shown in formula I:
- A represents divalent alkylene or alkenylene group having from about 2-8 carbon atoms; and R x and R 2 independently represent hydrogen, or organic groups optionally substituted w th a variety of moieties such as, for example, halogen, amino, carbonyl, sulfonyl, trifluoromethyl, lower alkyl, lower alkoxyl, etc.; or R 2 and R 2 together with the nitrogen to which they are attached form a five to seven-membered heterocyclic ring, such as, for example, pyrrolidinyl, piperazinyl, lower alkyl piperazinyl, piperidyl, thiomorpholinyl, morpholinyl or hexahydroazepinyl.
- R x and R 2 independently represent hydrogen, or organic groups optionally substituted w th a variety of moieties such as, for example, halogen, amino, carbonyl, sulfonyl, trifluoromethyl, lower alkyl, lower
- the tricyclic ring system may optionally be substituted with a variety of groups such as, for example, halogen, amino, carbonyl, sulfonyl, perfluoroalkyl, such as trifluoromethyl, lower alkyl, and lower alkoxyl, etc.
- the sulfur atom in formula I above may optionally be present as a sulfoxide.
- the thioxanthenes useful in the invention have the structural skeletons shown in formulas II and III:
- R' is hydrogen or an alkyl group
- R and R ⁇ independently represent hydrogen or alkyl
- R and R x together form a 5, 6, or 7-membered heterocyclic ring such as, for example, pyrrolidino, piperidino, morpholino or piperazino
- A is a 5, 6, or 7-membered heterocyclic ring such as, for example, pyrrolidino, piperidino, morpholino or piperazino.
- the 5, 6, or 7-membered heterocyclic ring may optionally be substituted with a variety of moieties such as halogen, amino, carbonyl, sulfonyl, perfluoroalkyl, lower alkyl, and lower alkoxy, etc.
- the tricyclic ring system may optionally be substituted with a variety of groups such as, for example, halogen, amino, carbonyl, sulfonyl, perfluoroalkyl, such as trifluoromethyl, lower alkyl, and lower alkoxyl, etc.
- Compounds suitable for use in the methods of the invention include single enantiomers, racemates and geometric isomers of compounds having the structural skeletons of Formulas I, II, or III, and the structures and compounds described below. It further includes mixtures of enantiomers and geometric isomers of these structures and compounds.
- Examples of drugs in the Phenothiazine family which are effective in blocking the appearance of paired helical filament epitopes include Promazine, Triflupromazine, Methotrimeprazine, Acetophenazine, Fluphenazine, Perphenzine, Prochloroperazine, Mesoridazine and Thoridazine. These and other similar phenothiazine compounds are described in U.S. Patent Nos. 2,921,069; 2,837,518; 2,860,138; 2,902,484; 3,194,733; 3,084,161; 2,519,886; 2,645,640; and 2,985,654, which are hereby incorporated by reference.
- Examples of drugs in the thioxanthene family that are effective in blocking the appearance of paired helical filament epitopes are Chlorprothixene and Thiothixene.
- Representative thioxanthenes are described in U.S. Patent Nos. 3,310,553 and 2,951,082, which also are hereby incorporated by reference.
- Representative phenothiazine compounds useful in practicing the method of this invention are:
- U.S. Patent No. 2.921.069 Compounds of the general formula: wherein Z is -S- or -SO-; Y is trifluoromethyl; R is hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxyl; A represents a divalent, straight or branched aliphatic chain containing 2 to 6 carbon atoms; and R and R 2 are either hydrogen, lower alkyl or divalent groups which together with the nitrogen to which they are attached form a five to seven-membered heterocyclic ring, such as pyrrolidinyl, piperazinyl, lower alkyl piperazinyl, piperidyl, thiomorpholinyl, morpholinyl or hexahydroazepinyl.
- Z is -S- or -SO-
- Y is trifluoromethyl
- R is hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxyl
- A represents a divalent, straight or
- Z is -S-; Y is a trifluoromethyl in the 2 or 4 position; R is hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy in the 6 or 8 position; A is a divalent, straight or branched aliphatic chain containing 2 to 5 carbon atoms; and R and R 2 represent either hydrogen, lower alkyl or divalent groups which together with the nitrogen to which they are attached 'orm a five to six-membered heterocyclic ring, such as pyrrolidinyl, piperazinyl, lower alkyl piperazinyl, piperidyl, thiomorpholinyl or morpholinyl.
- Still more advantageous compounds of this invention are represented by the above structural formula wherein: Z is -S-; Y is trifluoromethyl in the 2 or 4 position; R is hydrogen; A is either a divalent, straight aliphatic chain containing 2 to 4 carbon atoms or a divalent, branched aliphatic chain containing 2 to 5 carbon atoms; and R and R 2 represent either hydrogen, lower alkyl or divalent groups which together with the nitrogen to which they are attached form a five to six-membered heterocyclic ring, such as pyrrolidinyl, piperazinyl, lower alkyl piperazinyl, piperidyl, thiomorpholinyl or morpholinyl.
- the most preferred compounds are represented by the structural formula wherein: Z is -S-; Y is trifluoromethyl in the 2 position; R is hydrogen; A is a chain represented by the structure: —CH 2 -CH—CH 2
- R 3 wherein: R 3 is hydrogen, methyl or ethyl; and R x and R 2 represent lower mono-or dialkyl or divalent groups which taken together with the nitrogen to which they are attached form a five to six-membered heterocyclic ring, such as pyrrolidinyl, piperazinyl, lower alkyl piperazinyl, piperidinyl, thiomorpholinyl or morpholinyl.
- lower alkyl or lower alkoxyl refer to aliphatic groups having not more than 4 carbon atoms and preferably not more than 2 carbon atoms, as indicated.
- Y is selected from the class consisting of a sulphur atom and the SO and S0 2 groups
- X is selected from the class consisting of a hydrogen atom, a methyl, a methoxy, an ethyl and an ethoxy group
- Z is selected from the class consisting of the monomethylamino, monoethylamino, dimethylamino, diethylamino, pyrrolidino and piperidino groups.
- X is a halogen atom having an atomic number greater than 9 but less than 53; R is a member of the group consisting of hydrogen and lower alkyl groups whose combined number of carbon atoms is less than 6; and n is a natural number less than 3.
- A is a divalent saturated aliphatic hydrocarbon radical with a straight or branched chain containing from 2 to 6 carbon atoms;
- R is a hydrogen atom, or a lower alkyl, aryl or arylalkyl group;
- Y and x represent a hydrogen or halogen atom, or a lower alkyl, alkoxy or aryl or aryloxy group, preferably (in the case of Y) in the 1- or 3- position.
- the phenothiazine ring may carry a substituent in the form a methyl group.
- lower alkyl means an alkyl group containing not more than 6 and preferably not more than 4 carbon atoms.
- r is 1 or 2;
- X is hydrogen, halogen (preferably chloro) , trifluoromethyl, lower alkyl, lower alkoxy, lower alkanoyl, lower alkyl mercapto, trifluoromethylmercapto, and lower alkysulfonyl (preferably methylsulfonyl) ; and
- Y is higher alkyl, higher alkenyl, higher alkynyl, aryl, ⁇ -carboalkoxy (higher alkyl) or diphenyl (hydroxymethyl) .
- the terms "higher alkyl,” “higher alkenyl” and “higher alkynyl” as employed herein include both straight and branched chain radicals of more than five carbon atoms.
- ⁇ -carboalkoxy as employed herein, includes substituents derived from hydrocarbon carboxylic acids of more than 6 carbon atoms, and may be represented by the formula:
- n is a positive integer of more than 6 and is preferably a positive integer of from 7 to 12.
- aryl as employed herein includes substitutents derived from moncyclic and bicyclic aryl carboxylic acids, and may be substituted or unsubstituted and further may be represented by the formulae:
- each R is hydrogen, lower alkyl, lower alkoxy or halogen (e.g. chloro or bromo) .
- R is preferably hydrogen, lower alkyl or lower alkoxy, and most preferably, is hydrogen or lower alkyl.
- aryl carboxylic acids which may be employed include benzoic, o-toluic, 2,6-dimethylbenzoic, 2,6-dimethylanisic, o-bromobenzoic, o-chlorobenzoic, 2,6-dichlorobenzoic, naphthoic acid, dimethylnaphthoic acid, and other like acids.
- the preferred compounds are those wherein X is chloro or trifluoromethyl and Y is a higher alkyl, higher alkenyl or higher alkynyl radical of from six to fourteen carbon atoms, lower alkyl- of lower alkoxy-substituted aryl, or ⁇ -carboaloxy (higher alkyl) or less than 13 carbon atoms.
- Particularly preferred are those compounds wherein X is tifluoromethyl and Y is a higher alkyl radical of from nine to fourteen carbon atoms.
- X is S, SO, or S0 2 ; and each of ⁇ R 1 and R 2 is a member selected from the group consisting of alkyl radicals containing from 1 to 4 carbon atoms; and n is an integer from 1 to 2.
- R 1 and R are members of the class consisting of hydrogen atoms and alkyl groups (for example, methyl, ethyl and propyl) ; R 3 and R 4 represent alkyl groups (for example, methyl, ethyl, propyl, butyl) ; and n represents an integer greater than 1 (n may conveniently represent, for example, 2, 3, 4 or 5) .
- the benzene nuclei may be substituted by alkyl or alkoxy groups. It should be understood that the designation:
- CRR 2 groups are identical, branched aliphatic chains in which successive CR 1 R 2 groups are identical, and branched aliphatic chains in which successive CR ⁇ j groups may be different.
- the CR- ⁇ designation includes the branched chain:
- R is a hydrogen, chlorine or bromine atom, or a methyl or methoxy group in the 6- or 8- position
- X is either a chlorine or a bromine atom in the 1- of 3- position
- A is a divalent, straight or branched aliphatic chain containing from 2 to 5 carbon atoms
- R ⁇ and R 2 are either individual methyl or ethyl groups or divalent groups which together with the adjacent nitrogen atom form a mononuclear heterocyclic ring.
- A represents an alkylene group containing from 2 to 5 carbon atoms and R x and R 2 each represent a methyl or ethyl group or together represent the atoms necessary to complete a pyrrolidine, piperidine or morpholine nucleus.
- Y is a bivalent hydrocarbon radical of from 2 to 5 carbon atoms;
- R is a lower alkyl group;
- R' is a hydrogen or lower alkyl;
- A is a member of the group consisting of saturated and unsaturated aliphatic hydrocarbon groups and hydroxyalkyl groups including ethers and esters of the hydroxy group.
- Typical examples of the group represented by R are methyl, ethyl and propyl.
- Representative of A are groups such as methyl, ethyl, allyl, propragyl, butenyl, 2-hydroxyethyl,
- 2-carbamoylethyl and the like. Included in the group Y are ethylene, propylene, isopropylene, butylene, and the like. Methods for preparing these compounds are described in U.S. Patent No. 2,985,654. Representative thioxanthene compounds useful in practicing the methods of this invention are:
- R is hydrogen or, when taken together with R lf forms a single bond
- R is selected from the group consisting of hydrogen and lower alkyl or, when taken together with R forms a single bond
- R 2 is selected from the group consisting of hydrogen and lower alkyl
- R 3 and R when taken separately are selected from the group consisting of hydrogen and lower alkyl
- R 3 and R 4 when taken together with the nitrogen atom to which they are attached form a cyclic member selected from the group consisting of pyrrolidino, piperidino, morpholino and 4-lower alkylpiperazino
- A is selected from the group consisting of dialkylamino , 4-alkylpiperaz inyl ,
- X is a hydrogen, a halogen selected from the group consisting of chlorine, bromine, fluorine and iodine, a straight or branched chain alkyl radical having from 1 to about 4 carbon atoms, and a straight or branched chain alkoxy radical having with from 1 to 4 carbon atoms; and
- R 1 is a tertiary amino group which advantageously is a dilower-alkylamino, 1-piperidyl, 1-pyrrolidyl or 4-morpholinyl group.
- One or more of the hydrogens attached to the trimethylene side chain may be substituted by a lower alkyl group provided the total number of carbons in all substituent alkyl groups does not exceed 4.
- one or more r f the trimethylene hydrogens is substituted by an alkyl group, one of the alkyl substituents can be linked with R 1 to form a heterocyclic ring including the nitrogen atom.
- This invention also includes salts of the -above defined bases formed with non-toxic organic and inorganic acids.
- Such salts are easily prepared by methods known to the art.
- the base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqueous immiscible solvent, such as thyl ether or chloroform, with the desired salt separating directly.
- aqueous miscible solvent such as acetone or ethanol
- aqueous immiscible solvent such as thyl ether or chloroform
- Exemplary of such organic salts are those with aleic, enesalicyclic, methysulfonic.
- Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sufuric, sulfamic, phosphoric and nitric acids.
- salts may also be prepared by the classical method of dobule decomposition of appropriate salts which is well known in the art. Those skilled in the art would recognize that this invention includes the use of enantiomers, homologs and isomers of the above-identified compounds.
- These compounds may be formulated into pharmaceutical dosage forms by well recognized methods.
- the compounds described above may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- a pharmaceutical formulation comprising one of the above compounds and a pharmaceutically acceptable carrier.
- One or more of these compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.
- compositions containing these compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and dinintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylen oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbit
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, olive oil, sesame oil or coconut oil, or in a mineral such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations.
- These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
- the emulsions may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
- compositions may also contain a demulcent, a preservative and flavoring and coloring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water. Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono-or-diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the above described compounds may also be administered in the form of suppositories for rectal administration of the drug-.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- the above-identified compounds may be administered parenterally in a sterile medium.
- The"drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
- adjuvants such as local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
- Dosage levels of the order of from about 0.1 mg to about 2500 mg per day are useful in the treatment of the above-indicated.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
- Preferred compounds are: Compound Name
- Triflupromazine N,N-Dimethyl-2- (trif luoromethyl) -1 OH- phenothiazine-10-propanamine
- Chlorprothixene 3- (2Chloro-9H-thioxanthen-9- ylidene)-N,N-dimethy1-1-propanamine
- Okadaic acid was obtained from Moana Biochemical (Honolulu) , anisomycin was obtained from Sigma, and alkaline phosphatase was obtained from Boehringer Mannheim. 32 P-orthophosphoric acid was purchased from NEN, and 35 S-l-methionine was purchased from ICN Biomedicals.
- RPMI 1640 medium for routine growth of MSN cells, and phosphate-free and methionine-free RPMI media were obtained from GIBCO BRL.
- Antibodies T3P and tau46 were provided by Dr. Virginia Lee of rhe University of Pennsylvania. Monoclonal antibodies 188 and 147 were raised against highly enriched pair helical filament preparations and were provided by Abbott Laboratories. Ell is a polyclonal antiserum against the human exon 11 peptide of tau and was provided by Dr. Hana Kseizak-Reding of Albert Einstein College of Medicine of Yeshiva University. Tau-1 was obtained from Dr. Lester Binder of UAB.
- SMS-MSM-A human neuroblastoma cell line was cloned from a population of SMS-MSN cells obtained from the laboratory of Dr. June Biedler (Sloan-Kettering, New York, NY) , and was deposited with the American Type Culture Collection in Rockville, Maryland on February 2, 1993, and catalogued as ATCC # CRL 11253.
- the deposited human neuroblastoma cell line was tested for viability and determined viable on February 9, 1993.
- the neuroblastoma cells were grown in T75 flasks in RPMI 1640 medium supplemented with 15% fetal calf serum.
- OkA was dissolved in dimethyl sulfoxide (DMSO) and aliquots were added to Krebs-Ringer- phosphate buffer (KRP) containing 0.122 M NaCl, 4.9 mM KC1, 1.3 mM CaCl 2 , 1.6 mM Na 2 HP0 4 , and 10 mM dextrose (pH 7.4) to produce the required concentration. Control samples were incubated with similar aliquots of the DMSO vehicle, and the final concentration of DMSO was maintained below 0.1%. Before incubation, the growth medium was aspirated off from each flask, and replaced with KRP containing either vehicle or OkA. The flasks were incubated at 37°C for the appropriate durations.
- KRP Krebs-Ringer- phosphate buffer
- MSN cells were pelleted, resuspended in 250 ⁇ l cold Tris-buffered saline (TBS) containing 4 mM phenylmethylsulfonyl fluoride (PMSF) , 2 mM EGTA, and 25 ⁇ M leupeptin, and disrupted by sonicating with a 2 second pulse.
- PMSF phenylmethylsulfonyl fluoride
- 2 mM EGTA 2 mM EGTA
- 25 ⁇ M leupeptin 25 ⁇ M leupeptin
- the flasks were rinsed with cold Tris buffered saline (TBS) , and the entire cell suspension was centrifuged at 3000 g for 5 minutes in order to collect the cells.
- TBS Tris buffered saline
- the cell pellets were resuspended in 250 ⁇ l TBS containing 4 mM PMSF and 2 mM EGTA, and boiled for 10 minutes.
- the heat stable proteins were assayed for protein by a micro BioRad procedure.
- Electrophoresis and Blotting Aliquots of heat-treated supernatant containing 20 ⁇ g protein were boiled with electrophoresis sample buffer and loaded onto mini 10% SDS-PAGE gels. The gels were electrophoretically transferred to nitrocellulose membrane and immunolabelled as previously described (Vincent, I. and Davies, P. PNAS USA 87:4840-4844 (1990)).
- MSN cells were preincubated at 37°C for 1 hour with KRP in the absence or presence of 100 mM anisomycin. At the end of this time, 1 ⁇ M OkA was introduced into the appropriate flasks, and the samples incubated a further 90 minutes. Samples were then prepared for Western blot analysis according to routine protocol.
- the human neuroblastoma cell line SMS-MSN expresses tau protein as a doublet of apparent molecular weights 57 and 60 kDa. These proteins were detected with antibodies Alz-50, Tau-1, PHF-1, NP8 and T3P when 20 ⁇ g of heat-stable protein was utilized for SDS-PAGE and Western blot analysis (0 minute control, Figure 1) .
- MSN cells with OkA As a first step in investigating the role of protein phosphatases on these various epitopes, MSN cells with OkA, a cell- permeable protein phosphatase inhibitor (Bialojan, C. and Takai, A. J. Biochem. 256:283-290 (1988)).
- the monoclonal antibody 188 which recognizes primary sequence in tau was used as a negative control in these experiments. While the 0.1% dimethyl sulfoxide (DMSO) vehicle produced no changes (see 4 hour control, Figure 1) , a 30 minute exposure to 1 ⁇ M OkA resulted in a marked induction of the phosphorylated tau epitopes, PHF-1, NP8, and T3P. In addition, OkA treatment induced the appearance of PHF-1, NP8, and T3P epitopes on several higher molecular weight proteins. Both PHI and T3P reactivities were observed with a 68-kDa protein ( Figure 1) .
- DMSO dimethyl sulfoxide
- Figure 3 shows the effects of 100 ⁇ M anisomycin, a protein synthesis inhibitor, on the OkA-induced effects on tau. Consistent with their rapidity, the increases in immunoractivity of Alz-50, 188, PHF-1, NP8, or T3P and the shift in molecular weight do not require protein synthesis. Moreover, the disappearance of Tau-1 immunoreactivity that occurred as a result of OkA treatment was also observed in the presence of anisomycin ( Figure 3) .
- phosphatase 1 0.1-0.5 mM
- phosphatase 2A is 1 nM
- the IC-50 for phosphatase 2B i.e., the Ca 2+ /CAM-dependent phosphatase, Calcineurin
- phosphatase 2C i.e., the Mg 2+ -dependent phosphatase
- Optimal inductions in PHF-1, NP8, and T3P immunoreactivities occur at 50 nM, a concentration 50-fold that of the IC-50 for phosphatase 2A, making it likely that phosphatase 2A plays an important role in turnover of these epitopes.
- this concentration is 2-10 fold less than the IC-50 for phosphatase 2B, it is unlikely that either of these phosphatases play role in regulation of these epitopes.
- Phosphorylation at the Tau-1 site is favored at or over 1 ⁇ M, although some inhibition in Tau-1 immunoreactivity is observed at 50 nM OkA.
- it is more likely that phosphatase 1 is involved in turnover of the phosphatase at the Tau-1 site, although a role for phosphatase 2A cannot be excluded.
- phosphatase 2A The suggested role of phosphatase 2A in the formation of the PHF-1, T3P and NP8 epitopes in MSN cells indicates that this phosphatase is crucial in determining the phosphorylation state of both normal and paired helical filament-like epitopes in tau, and may be an important enzyme in tau metabolism.
- the immunoreactivity of monoclonal antibodies Alz- 50, PHF-1, TG3, TG4 , MC2, MC6, and MC15 with normal and Alzheimer's brain tissue, and with MSN cells before (MSN-) and after treatment (MSN+) with okadaic acid was examined, and the results are presented in Figure 7.
- the data from brain tissue are the mean values derived from studies of mid-temporal cortex from five normal cases and five cases of Alzheimer's Disease.
- Values from MSN cells are from a single experimental series in which 1 micromolar okadaic acid was added to triplicate MSN cell cultures for 90 minutes prior to harvest of the cells. Each sample (tissue or cell homogenate) was assayed at 8 dilutions in duplicate.
- the units on the Y axis are arbitrary units of immunoreactivity. In all cases, it is clear that okadaic acid produces increases in immunoreactivity in MSN cells, and that this increase is similar in extent to the difference between normal and Alzheimer's brain tissue.
- MSN-A cells expressing PHF epitopes were incubated with 100 ⁇ M Trifluoperazine (TFP) , 100 ⁇ M Chlorpromazine (CPZ) or 0.2% DMSO vehicle (control) for 2 hours at 37°C.
- the cells were isolated by centrifugation, boiled for 10 minutes and 25 ⁇ g protein from the resulting heat stable supernatants were loaded per lane on an SDS-PAGE gel. The gel was electrophoretically transferred to nitrocellulose membrane and then immunostained with PHF-1.
- both TFP and CPZ greatly decreased the production of paired PHF epitopes by the neuroblastoma cells.
- the control shows that without the addition of TFP or CPZ, there was production of PHF epitopes by the neuroblastoma cells.
- Frontal and cortical brain tissue specimens were obtained at autopsy from chronic schizophrenic patients chronically treated with chlorpromazine and analyzed using the
- the brain tissue from approximately the same number of (age matched) normal controls and
- Alzheimer's disease patients were also analyzed and are presented in the Figures as negative ana positive controls
Abstract
On décrit des procédés qui permettent de prévenir ou traiter la maladie d'Alzheimer et consistent à administrer à un patient une quantité d'une phénothiazine ou d'un thioxanthène efficace pour prévenir ou diminuer l'accumulation d'épitopes anormalement phosphorylés, à filaments hélicoïdaux appariés, qui sont associés à la maladie d'Alzheimer.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32793/95A AU708682B2 (en) | 1994-08-08 | 1995-08-07 | Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes |
EP95929441A EP0778773A1 (fr) | 1994-08-08 | 1995-08-07 | Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes |
JP8507474A JPH11506414A (ja) | 1994-11-30 | 1995-08-07 | フェノチアジン類および/またはチオキサンテン類を用いてアルツハイマー病を治療および/または予防する方法 |
KR1019970700943A KR970704445A (ko) | 1994-08-08 | 1997-02-10 | 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28733994A | 1994-08-08 | 1994-08-08 | |
US08/287,339 | 1994-08-08 | ||
US34675794A | 1994-11-30 | 1994-11-30 | |
US08/346,757 | 1994-11-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996004915A1 WO1996004915A1 (fr) | 1996-02-22 |
WO1996004915A9 true WO1996004915A9 (fr) | 1996-04-11 |
Family
ID=26964404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/010110 WO1996004915A1 (fr) | 1994-08-08 | 1995-08-07 | Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0778773A1 (fr) |
KR (1) | KR970704445A (fr) |
AU (1) | AU708682B2 (fr) |
CA (1) | CA2196529A1 (fr) |
WO (1) | WO1996004915A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB9713484D0 (en) * | 1997-06-27 | 1997-09-03 | Smithkline Beecham Plc | Neuroprotective vanilloid compounds |
DE19842416A1 (de) * | 1998-09-16 | 2000-04-13 | Max Planck Gesellschaft | Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden |
GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
EP1470818B1 (fr) * | 2003-04-25 | 2006-07-26 | Neuro3D | Utilisation de dérivés de phénothiazine pipérazine pour la préparation d'un médicament ayant des effets neuroprotecteurs et/ou neurotrophiques sur le SNC et/ou SNP |
JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
AU2005326962A1 (en) | 2004-12-22 | 2006-08-17 | Bellus Health (International) Limited | Methods and compositions for treating amyloid-related diseases |
CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
CN103735554B (zh) | 2006-03-29 | 2018-03-20 | 维斯塔实验室有限公司 | 蛋白聚集抑制剂 |
CN101460222B (zh) * | 2006-03-29 | 2013-12-04 | 维斯塔实验室有限公司 | 锍化合物及其用途 |
WO2009019534A2 (fr) | 2006-10-12 | 2009-02-12 | Bellus Health (International) Limited | Procédés, composés, compositions et véhicules permettant de délivrer l'acide 3-amino-1-propane sulfonique |
GB0701970D0 (en) | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
ES2331282B1 (es) * | 2008-06-25 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) (45%) | Hidrazidas de sistemas heterociclicos y su uso en el tratamiento de enfermedades neurodegenerativas. |
DE102010062810B4 (de) | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
SI2673266T1 (sl) | 2011-02-11 | 2016-11-30 | Wista Laboratories Ltd. | Fenotiazin diaminijeve soli in njihova uporaba |
US8980884B2 (en) * | 2011-06-01 | 2015-03-17 | Wisconsin Alumni Research Foundation | Methods for treating Alzheimer's disease |
JP2023549174A (ja) * | 2020-11-04 | 2023-11-22 | グリアセルテック・インコーポレイテッド | クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物 |
US20240025868A1 (en) * | 2020-11-13 | 2024-01-25 | Icahn School Of Medicine At Mount Sinai | Phenothiazine compounds for the treatment of alzheimer's disease and other age-related and neurological diseases |
WO2023131606A1 (fr) * | 2022-01-04 | 2023-07-13 | Immungenetics Ag | Dosage spécifique de composés de phénothiazine destinés à être utilisés dans le traitement ou la prévention de la maladie d'alzheimer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2837518A (en) * | 1958-06-03 | Phenthiazine compounds | ||
US2902484A (en) * | 1954-04-27 | 1959-09-01 | Rhone Poulenc Sa | Phenthiazine derivatives and processes for their preparation |
NL108827C (fr) * | 1956-04-09 |
-
1995
- 1995-08-07 CA CA002196529A patent/CA2196529A1/fr not_active Abandoned
- 1995-08-07 AU AU32793/95A patent/AU708682B2/en not_active Ceased
- 1995-08-07 WO PCT/US1995/010110 patent/WO1996004915A1/fr not_active Application Discontinuation
- 1995-08-07 EP EP95929441A patent/EP0778773A1/fr not_active Withdrawn
-
1997
- 1997-02-10 KR KR1019970700943A patent/KR970704445A/ko not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU708682B2 (en) | Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes | |
WO1996004915A9 (fr) | Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes | |
Swartz et al. | Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors | |
Van Swieten et al. | Phenotypic variation in hereditary frontotemporal dementia with tau mutations | |
EP2853293B1 (fr) | Composés de thioninium et leur utilisation | |
CA2207333C (fr) | Utilisation de nebivolol comme agent anti-atherogene | |
EP2373660B1 (fr) | Sels de xanthylium 3,6-disubstitues comme medicaments | |
KR20070013265A (ko) | 아세틸콜린에스테라아제 억제제 및(3aR)-1,3a,8-트리메틸-1,2,3,3a,8,8a-헥사히드로피롤로[2,3-b]인돌-5-일 페닐카르바메이트에 의한 조합 요법 | |
KR20070116900A (ko) | 라이아노딘 수용체 (ryr2)에서의 누출을 표적화하는신규한 항부정맥 및 심부전 약물 | |
GB2205495A (en) | New uses of dopamine receptor agonists | |
US6306857B1 (en) | Methods for treating or preventing alzheimer's disease using substituted 1-aryl-3-piperazin-1′-yl propanones | |
JP2008502602A (ja) | タウオパシーの治療のための組成物および方法 | |
US6228878B1 (en) | Methods for treating or preventing alzheimer's disease using substituted 2-aryl-3-morpholinopropanones | |
US6214994B1 (en) | Certain substituted 1-aryl-3-piperazin-1′-yl propanones | |
ZA200404274B (en) | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure. | |
WO2011009193A1 (fr) | Thérapie de combinaison pour des tauopathies | |
US6489355B2 (en) | Methods of inhibiting the effects of amyloidogenic proteins | |
JP4491229B2 (ja) | ミトコンドリアを保護するための医薬を調製するためのチアゾール誘導体の使用 | |
JPH11506414A (ja) | フェノチアジン類および/またはチオキサンテン類を用いてアルツハイマー病を治療および/または予防する方法 | |
AU5588799A (en) | Method of treating neurodegenerative diseases | |
JP7170875B2 (ja) | アミロイド性脳神経疾患の治療用組成物および治療方法 | |
JPH07133225A (ja) | 毛様体筋緊張緩和剤 | |
MXPA97003636A (en) | Use of aril-morpholine-, tiomorfolino- or piperacino-propanones replaced for the treatment to prevent alzhei disease | |
Figueras et al. | Antipsychotic drugs | |
GB2309167A (en) | The use of azaspiranes in the treatment of Alzheimer's disease |